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Urachal cancer (UrC) is a rare but aggressive cancer. Due to overlapping histomorphology, discrimination of urachal from primary
bladder adenocarcinomas (PBAC) and adenocarcinomas secondarily involving the bladder (particularly colorectal
adenocarcinomas, CRC) can be challenging. Therefore, we aimed to give an overview of helpful (immunohistochemical)
biomarkers and clinicopathological factors in addition to survival analyses and included institutional data from 12 urachal
adenocarcinomas. A PubMed search yielded 319 suitable studies since 1930 in the English literature with 1984 cases of UrC
including 1834 adenocarcinomas (92%) and 150 nonadenocarcinomas (8%). UrC was more common in men (63%), showed a
median age at diagnosis of 50.8 years and a median tumor size of 6.0 cm. No associations were noted for overall survival and
progression-free survival (PFS) and clinicopathological factors beside a favorable PFS in male patients (p = 0 047). The
immunohistochemical markers found to be potentially helpful in the differential diagnostic situation are AMACR and
CK34βE12 (UrC versus CRC and PBAC), CK7, β-Catenin and CD15 (UrC and PBAC versus CRC), and CEA and GATA3
(UrC and CRC versus PBAC). Serum markers like CEA, CA19-9 and CA125 might additionally be useful in the follow-up and
monitoring of UrC.
1. Introduction
The urachus is a remnant of the fetal structure connecting the
allantois and the fetal bladder. During early fetal develop-
ment, the urachus usually regresses to form an obliterated
fibromuscular canal, known as the median umbilical liga-
ment [1–4]. Failure of complete luminal obliteration has
been described in up to one-third of adults and can rarely
lead to various anomalies including cysts, fistulas, and diver-
ticula or rarely malignant transformation [2, 5].
Our understanding of urachal cancer (UrC) has evolved
since the seminal studies by Begg [6] in the 1930’s following
the first report by Hue and Jacquin [7] in 1863 and earlier
works of Cullen in 1916 [8]. UrC is a very rare but highly
malignant tumor entity with an incidence of <1% of all blad-
der cancers [1, 9, 10]. Establishing the diagnosis of UrC can
be challenging for the urologist, pathologist, and radiologist
and usually requires a multidisciplinary approach. In terms
of histopathology, many overlapping features with the main
differential diagnostic entities exist. While the diagnostic
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criteria adapted and established by Sheldon et al. [11] are
most widely used, Gopalan and colleagues [1] modified these
criteria and Paner and colleagues proposed diagnostic cri-
teria for nonglandular type UrC [12].
Recently, Paner and colleagues also gave a review on the
diagnosis and classification of urachal epithelial neoplasms
[13]. To furthermore give a current overview of the clinical
and therapeutical implications of UrC, we have recently con-
ducted a meta-analysis of the literature including 1010 cases
of UrC [14].
Histologically, urachal adenocarcinomas (which are the
most common carcinomas of urachal origin) overlap with
their main differential diagnostic entities, that is, primary
bladder adenocarcinomas and colorectal adenocarcinomas.
The present work therefore aims to provide an overview
and summary of the immunohistochemical biomarkers in
UrC and their potential role in the diagnosis of such
tumors. It is combined with clinicopathological evidence
and its data is collected from the published literature since
1930. Additionally, it is supported by our own data of
immunohistochemical expression in 12 UrC cases with 11
different antibodies including the report of GATA3 expres-
sion in this disease.
2. Literature Review and Statistics
A PubMed search was conducted using the string [“urachus
carcinoma” OR “urachus cancer” OR “urachal carcinoma”
OR “urachal cancer”] which returned 854 results (end of data
acquisition: 08/2016). The algorithm of study selection is
illustrated in Figure 1. Information was extracted from whole
papers written in English language and from English
abstracts in case of other primary language. In case of differ-
ent entities in the papers, only information regarding UrC
was extracted. When available, survival data was recorded
for both overall survival (OS) and progression-free survival
(PFS). For statistical analyses, SPSS (v23; IBM, Armonk,
USA) was used. Pearson correlation analysis was conducted
when appropriate. Survival analyses were conducted using
the Kaplan Meier method with the log-rank test and univari-
able Cox analysis. When appropriate, continuous variables
were dichotomized at their median level for analysis of their
impact on survival.
3. Additional Data from Our Own Institution
The clinicopathological data of our cohort has been pub-
lished previously [15]. Immunohistochemical studies were
performed on formalin-fixed and paraffin-embedded urachal
adenocarcinoma tissue using a BenchMark ULTRA System
(Ventana Medical Systems, Tucson, USA) following manu-
facturer’s instructions. A total of 11 different antibodies were
performed on 12 cases of urachal adenocarcinomas from the
University Hospital of Essen including β-Catenin, CD15,
CDX2, CEA, CK7, CK20, GATA3, MLH1, MSH2, MSH6,
and PMS2 (Supplementary Table 1). The study was approved
by the ethic committee of the University Hospital of Essen
(16-6902-BO, 04.28.2016).
Further details on used antibodies, protocol information,
and results of the immunohistochemical analyses are dis-
played in Supplementary Table 1.
4. General Results of the Literature Review
Three hundred and nineteen studies were identified that con-
tained sufficient information on cases of UrC. The number of
publications has increased rapidly in the recent years with
169 (53%) publications since the year 2000 and 75 (24%)
studies from 2011–2016.
A total of 2154 cases of UrC were identified, with infor-
mation on UrC histology available in 1984 cases (92%), of
which 1834 (92%) were adenocarcinomas. The majority of
studies with information on UrC cases were case reports
(74%), while contributing only a minor part to the total num-
ber of cases (16%). In 1491 cases, gender information was
available with evidence showing that most UrC cases
occurred in men (63%) compared to women (37%). The
mean and median age were 48.6 and 50.8 years, respectively
(range: 0.3–86.0 years), and tumor size 7.1 cm and 6.0 cm,
respectively (range: 0.5–25.0 cm). Data on tumor grades were
sporadic and inconsistent and could not be further analyzed.
Survival data were available in 76 cases (adenocarcinomas:
n = 60, nonadenocarcinomas: n = 16) with a median follow-
up of 12 months in the total cohort (range: 1–62 months).
The median OS for the entire cohort was 46.8 months (ade-
nocarcinomas: 42.7 months) with a 1-year survival of 86%
(adenocarcinomas: 86%), 3-year survival of 63% (adenocarci-
nomas: 59%), and a 5-year survival of 41% (adenocarci-
nomas: 35%). The median PFS for the entire cohort was
46.6 months (adenocarcinomas: 41.1 months) and 75% at
1-year (adenocarcinomas: 72%), 60% at 3 years (adenocarci-
nomas: 55%), and 39% at 5 years (adenocarcinomas: 33%). It
is important to note that some of the survival data derives
from older papers with different treatment strategies that
might have affected the outcome analysis. In fact, recent
epidemiological studies demonstrate higher survival rates
(5-year overall survival of approximately 50%) due to
advances in the surgical and medical management of this dis-
ease [16].
Detailed clinicopathological data are listed in Table 1.
Data on UrC adenocarcinomas were collected from these ref-
erences [1, 3, 4, 9–11, 15–251].
5. Specific Review Data: Adenocarcinomas
Histopathologically, both primary adenocarcinomas of the
bladder and urachal adenocarcinomas show similar subtypes
although their distribution differs [21, 252, 253]. In invasive
urachal adenocarcinoma, the following four subtypes are
described in the 2016 WHO classification: mucinous (colloi-
dal) type with preponderance of extracellular mucin and
malignant epithelia floating within, enteric (intestinal) type
with preponderance of malignant stratified epithelium
resembling colorectal adenocarcinomas,mixed type with nei-
ther a mucinous nor an enteric pattern prevailing, not other
specified (NOS) type with a pattern not easily identifiable as
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mucinous or enteric type, and signet ring cell type with signet
ring cell morphology prevailing.
It is important to note that the concept of mucinous cys-
tic tumors as recently proposed by Amin et al. [17] was not
applied for this study due to the lack of such a classification
in the older literature. In their work, Amin et al. described a
distinct subgroup of urachal neoplasms with predominant
cystic appearance in analogy to similar neoplasms in the
ovary. This includes mucinous cystadenomas, mucinous cys-
tic tumor of low malignant potential (MCTLMP), and
mucinous cystadenocarcinoma with microinvasion or frank
invasion. However, although in cox analyses tumor size was
not associated with survival, not larger but smaller tumor size
exhibited a higher hazard ratio for OS possibly giving support
to the concept of favorable prognosis of mucinous cystic
lesions of urachal origin [17].
In a population-based study from Wright and colleagues
including 151 UrC adenocarcinomas and 1374 primary blad-
der adenocarcinomas, the mucinous/colloid pattern was
detected in 48% of UrC adenocarcinomas [16]. Also in our
analysis, the mucinous type represented the most common
special type of urachal adenocarcinomas (57%) (Table 1,
Figure 2(a)). In Wright and colleagues’ work, the second
most common pattern was the NOS type (39%), which in
our analysis accounted for 14%. However, in their analysis,
the enteric type was not explicitly mentioned, which com-
prised 15% in our study. Additionally, they described the sig-
net ring cell type and the mixed type in 7% each, which
comprised 6% and 8% in our analysis, respectively. The prog-
nostic value of these histopathologic features, however,
remains to be established while a more favorable clinical
course for UrC adenocarcinomas as compared to primary
bladder adenocarcinomas was found [16]. Additionally, pres-
ence of signet ring cell morphology and higher tumor grade
were identified of unfavorable prognostic value in some [10,
21, 157, 192, 221] but not all series [24] of UrC adenocarci-
nomas. Regarding signet ring cell morphology, this may
result from the differing definitions and lack of consistent
cut-off on the amount of signet ring cells across the different
studies. In our survival analysis from cases of the literature,
we could not detect an influence of type of UrC adenocarci-
noma on OS, but a borderline influence on PFS in terms of
a survival benefit for intestinal type UrC. However, this find-
ing was not consistent in further (Kaplan Meier) analyses,
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Figure 1: PRISMA flow diagram. The diagram illustrates the phases and selection criteria used for study selection in this work.
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Table 1: Review data of the cohort (a) and in association with survival data (b). UrC: urachal cancer; NOS: not otherwise specified; n/a: data
not available; UC: urothelial carcinoma; SCC: squamous cell carcinoma; npl.: neoplasms; HR: hazard ratio; CI: confidence interval; ref.:
reference group. ∗Data analysis was not feasible due to insufficient number of cases; ^Cut-off values were chosen after partition tests.
(a)
n %
Studies 319 100
Original study 72 22.6
Case report 235 73.7
Missing information 12 3.7
UrC total 1984 100
UrC adenocarcinoma total 1834 100
UrC adenocarcinoma specific type 1144 62.4
Mucinous 647 56.6
Enteric 172 15.0
NOS 157 13.7
Mixed 96 8.4
Signet ring 72 6.3
UrC adenocarcinoma type n/a 690 37.6
UrC nonadenocarcinoma 150 100
UrC nonadenocarcinoma specific type 124 82.7
UC 58 46.8
Sarcoma 34 27.4
SCC 26 21.0
Neuroendocrine npl. 6 4.8
UrC nonadenocarcinoma type n/a 26 17.3
Gender information available 1491 100
Male 936 62.8
Female 555 37.2
Age (mean/median) in years 48.6/50.8
Tumor size (mean/median) in cm 7.1/6.0
(b)
Overall survival Progression-free survival
HR 95% CI p HR 95% CI p
UrC type
Adenocarcinoma 2.031 0.452–9.117 0.355 4.782 0.626–36.506 0.131
Nonadenocarcinoma ref. ref.
UrC adenocarcinoma
Mucinous 0.888 0.192–4.095 0.879 0.736 0.203–2.667 0.641
Nonmucinous ref. ref.
UrC nonadenocarcinoma
UC n/a∗ n/a∗ n/a∗ n/a∗ n/a∗ n/a∗
Non-UC ref. ref.
Gender
Male 0.629 0.276–1.430 0.268 0.197 0.039–0.981 0.047
Female ref. ref.
Age^
<45 years 1.880 0.769–4.598 0.167 1.534 0.652–3.610 0.327
>45 years ref. ref.
Tumor size^
<7.0 cm 2.644 0.502–13.923 0.251 2.943 0.592–14.622 0.187
>7.0 cm ref ref.
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thus preventing further conclusions. Data density was too
low for any tumor grading-related analyses.
Regarding the gender distribution, our review data is sim-
ilar to epidemiological studies with preponderance of male
UrC patients (62.8%) [16]. While no significant influence of
gender was detectable on OS in our accumulated data from
the literature, male gender was associated with improved
PFS (p = 0 047), an effect which wasmainly related to the ade-
nocarcinoma part of the cohort (p = 0 009; Supplementary
Figure 1). This effect has not yet been mentioned in the liter-
ature while its cause remains to be elucidated. It seems not to
be related to median tumor size or age at diagnosis as these
factors were not associated with gender. Additionally, no sig-
nificant prognostic associations were noted for these two fac-
tors, neither in the total cohort nor in subgroup analyses.
6. Specific Review Data:
Nonadenocarcinoma Neoplasms
In addition to UrC adenocarcinomas, nonglandular ura-
chal tumors are included in the recent WHO 2016 classi-
fication. These are urothelial, squamous, neuroendocrine,
and mixed-type neoplasms, which are stated to account
for 4% to 27% of cases [12, 13, 253, 254]. These neo-
plasms are histologically and immunophenotypically simi-
lar to their counterparts elsewhere in the body [253].
Our analysis yielded 124 (of 150) cases of nonadenocar-
cinoma UrC with further classified histology. Urothelial car-
cinomas (UC) represented the largest group (n = 58, 47%)
(Table 1, Figure 2(b)) [3, 10–12, 19, 23, 46, 71, 82, 85, 127,
223, 255–267]. The second largest group was the group of
sarcomas (n = 34, 27%), however, with a large variety of dif-
ferent entities including childhood rhabdomyosarcoma
(embryonal, alveolar and NOS types) [268–272], leiomyo-
sarcomas [273–276], fibrosarcomas [277, 278], and also
some cases without further specification of the type of entity
[3, 11, 47, 279–281]. Attention has to be paid to the fact that
the reported sarcomas derive from a broad timespan with
different knowledge levels, respectively. Therefore, some of
these neoplasms would today be classified differently. In
addition to mesenchymal lesions, our analysis showed 26
cases of squamous cell carcinomas (SCC; 21%) [11, 71, 85,
105, 223, 282–291], followed by neuroendocrine neoplasms
including small cell carcinomas with 6 cases (5%) [9, 10,
12, 201]. In the remaining cases, information on nonadeno-
carcinoma entity was at least partly missing [3, 11, 19, 71, 85,
141, 292, 293] or included other entities such as yolk sac
tumors [187, 294, 295] or a neuroblastoma [296].
In addition to malignant urachal tumors, several other
intermediate and benign tumors or conditions of the urachus
have been reported some mimicking urachal cancer and thus
posing a differential diagnostic problem. Tumors or condi-
tions rated as intermediate include inflammatory myofibro-
blastic tumors (IMT) [297–300], a solitary fibrous tumor
(SFT) [301], desmoid fibromatoses [302, 303], a hemangio-
pericytoma [304], and a Castleman’s disease [305], while
benign tumors and conditions include dermoid cysts [301,
306], teratomas [307, 308], leiomyomas [309, 310], (fibrous)
hamartomas [311, 312], a hemangioma [313], a fibroade-
noma [314], malakoplakia [315], abscesses [316–318], a
xanthogranulomatous urachitis [319], a urachal tuberculosis
[320], actinomycosis [321–323], an endometriosis [324], a
perforated colonic diverticulitis [325], and even a fishbone
within an urachal cyst [326].
7. Biomarkers in Urachal
Cancer: Immunohistochemistry
Given the extensively overlapping histopathological features
of adenocarcinomas of urachal and primary bladder origin
on the one hand and secondary adenocarcinomas from
different sites on the other, biomarkers for differential
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Figure 2: Distribution of the different types of UrC (a) in urachal adenocarcinomas with available information of special type and (b) in
nonadenocarcinoma UrC with information of special type. UrC: urachal cancer; NOS; not otherwise specified; UC: urothelial carcinoma;
SCC: squamous cell carcinoma; NE npl.: neuroendocrine neoplasms.
5Disease Markers
diagnostic purposes are required. The most important differ-
ential diagnostic problems with significant impact on thera-
peutic decisions may be categorized as follows:
(1) Differentiation between invasion/metastasis of colo-
rectal adenocarcinomas and urachal adenocarci-
nomas. Exclusion of a possible invasion of this cancer
(to the bladder) is a necessary step for the definitive
diagnosis of UrC and of therapeutic relevance.
(2) Distinguishing urachal adenocarcinomas from those
of primary bladder origin has also a direct clinical
impact on the surgical treatment. In localized disease,
primary bladder adenocarcinomas are usually treated
with complete cystectomy while urachal adenocarci-
nomas mostly require partial cystectomy with en bloc
removal of the umbilical ligament and umbilicus
(radical versus partial cystectomy) with significantly
different impact on quality of life [4, 85].
(3) Identification of the origin of a (mucinous) adenocar-
cinoma of unknown primary is also important as ura-
chal adenocarcinomas frequently metastasize to
various organs, such as the bone, lung, and liver.
Identification of urachal origin of a (mucinous) ade-
nocarcinoma can have a direct therapeutic conse-
quence [4].
An overview of the immunohistochemical markers
assessed in urachal adenocarcinomas is provided in Table 2
and a representative example is illustrated in Figure 3. Further
detailed information is provided in Supplementary Table 2.
The immunohistochemical markersmost often employed
in the work up of adenocarcinomas of different sites usually
include Cytokeratin 20 (CK20) and CK7. In our analysis of
a total of 116 urachal adenocarcinomas, only 4 cases were
negative for CK20—an overall positive rate of 97% [1, 17,
23, 26, 27, 31, 36, 48, 56, 60, 62, 67, 74, 77, 86, 95, 99, 124–
126, 128, 148, 156, 163, 164, 216, 217, 220, 240, 245, 251,
327]. Considering the robust CK20 expression in adenocarci-
nomas of sites of differential diagnostic interest, CK20 has no
significant value in this setting.
In contrast, expression of CK7 in these tumors is widely
variable. In urachal adenocarcinomas, CK7 exhibited a
pooled reactivity rate of 51%, compared to considerable lower
rates in colorectal cancer (0–38%, Table 2, Supplementary
Table 2) [1, 17, 23, 26, 27, 31, 36, 48, 56, 60, 67, 74, 77, 86,
99, 124, 125, 156, 163, 164, 216, 217, 220, 240, 251, 255, 292,
327, 328]. However, similar to urachal adenocarcinomas, pri-
mary bladder adenocarcinomas constantly exhibited rela-
tively high CK7 reactivity rates (33%–70%), thus limiting
the value of CK7 in the discrimination between these two
entities [23, 329].
Additionally, CK20 and CK7 were the only markers with
sufficient data for survival analyses. However, no significant
influence of the CK20/CK7 expression profile on OS or PFS
was noted.
As a rather specific nuclear marker for intestinal epithe-
lia and corresponding adenocarcinomas, CDX2—a homeo-
box gene coding for a transcription factor with intestine
specificity—has been proposed for differential diagnostic
considerations. However, nuclear CDX2 reactivity was
evident in the majority of urachal adenocarcinomas (90%)
[1, 17, 23, 26, 31, 60, 99, 125, 126, 128, 216, 217, 240, 245,
251, 327, 330] and many primary bladder adenocarcinomas
(13%–83%) [329, 331]. In addition to its reactivity in almost
all colorectal adenocarcinomas, CDX2 immunopositivity has
been detected in considerable numbers in several adenocar-
cinomas from different sites such as the gastrointestinal
tract, pancreas, and ovary [330, 332]. Furthermore, CDX2
reactivity has been described in cystitis glandularis and
intestinal metaplasia of the bladder and glandular epithelia
of urachal remnants [23, 333–335]. Taken together, CDX2
is not helpful in the differential diagnosis of adenocarci-
nomas in the urinary bladder.
Another plausible biomarker in this context is β-Catenin,
a protein involved in cell-cell adhesion and gene transcrip-
tion regulation [336]. In normal cells, β-Catenin staining is
restricted to the membrane/cytoplasm, while in colorectal
adenocarcinomas, β-Catenin exhibits nuclear accumulation
due to mutation or loss of the adenomatous polyposis coli
(APC) gene then acting as a transcriptional activator [337].
While in colorectal adenocarcinomas nuclear β-Catenin
expression can be found in the majority of cases, nuclear β-
Catenin reactivity was detected in a low rate of primary blad-
der adenocarcinomas (0%–17%) [329, 338]. Similarly, in ura-
chal adenocarcinomas, nuclear β-Catenin expression was a
rare event. In our summary analysis, any type of nuclear β-
Catenin was detected in 9 of 63 cases (14%) [1, 17, 23, 26,
125, 216, 220, 328]. APC mutations, however, can be found
in urachal adenocarcinomas slightly more often than the
immunohistochemical results propose [20, 204]. From a dif-
ferential diagnostic point of view, nuclear β-Catenin expres-
sion may be useful in distinguishing primary bladder and
urachal adenocarcinomas from secondary bladder involve-
ment by colorectal adenocarcinomas. However, β-Catenin
is of no use in the differentiation of primary bladder from
urachal adenocarcinomas as both entities exhibit comparable
β-Catenin staining characteristics.
Further potential markers include Claudin-18 and Reg
IV, however, with no available data in primary bladder ade-
nocarcinomas. Claudin-18 has been reported to be of diagnos-
tic value especially in pancreatic and gastric cancer, but is
rarely expressed in colorectal adenocarcinomas [339–341].
Although exhibiting a positivity rate of 53% in the total num-
ber of urachal adenocarcinomas cases, it was found to have
only a low positivity rate (27%) in enteric type urachal adeno-
carcinomas, thus limiting its usefulness in UrC diagnostics
with regard to the largest group of intestinal-differentiated
colorectal adenocarcinomas [23]. Reg IV is associated with
the cellular phenotype of the intestine and expressed in vari-
ous cancers with intestinal differentiation such as gastric and
colorectal cancer [342]. In urachal adenocarcinomas, Reg
IV expression was detected in 85% of cases arguing against
its potential use in the differential diagnostics of adenocarci-
nomas detected in the bladder [23]. Both markers addition-
ally failed to demonstrate diagnostic value in signet ring cell
UrC compared to signet ring cell carcinoma of colorectal
origin [23].
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Further, possibly useful biomarkers of urachal adenocarci-
nomas with data of at least 10 cases are alpha-methylacyl-CoA
racemase (AMACR, p504s), CD15 (Leu-M1), carcinoem-
bryonic antigen (CEA), CK34βE12 (high-molecular weight
cytokeratin), GATA binding protein 3 (GATA3), mucin 2
(MUC2), and mucin 5AC (MUC5AC).
In urachal adenocarcinomas, AMACR was found to be
positive in a low number of cases (17%), while in colorectal
and primary bladder adenocarcinomas, a significantly
higher number (>66%) of cases exhibited AMACR-
reactivity [17, 77, 343, 344]. In contrast, CK34βE12 was more
frequently positive (67%) in urachal adenocarcinomas, while
being variably expressed in primary bladder or colorectal
adenocarcinomas [1, 26, 77, 125, 255, 345]. A comparable
distribution was detected for MUC2 andMUC5ACwith high
positivity rates in urachal adenocarcinomas (100% and 92%)
(a) (b) (c) (d)
(e) (f) (g) (h)
(i) (j)
Figure 3: A representative case of mucinous urachal adenocarcinoma. (a) Atypical cells floating in extracellular mucin. Focal signet ring cell
morphology is noticeable (H&E staining). The case exhibited a typical profile in further immunohistochemical studies with no reactivity for
CK7 (b) but positive reactivity for CK20 (c) and CDX2 (d, nuclear). As in all analyzed cases, no GATA3 reactivity was noted (e). In the
β-Catenin immunohistochemistry, a strong membranous and cytoplasmic but no nuclear reactivity was noted (f; inlay magnification 600x).
The immunohistochemical reactions against the MMR proteins all were positive, that is, MLH1 (g), PMS2 (h), MSH2 (i), and MSH6 (j).
Table 2: Useful immunohistochemical antibodies in the differential diagnosis of urachal adenocarcinoma (UrC), colorectal adenocarcinoma
(CRC), and primary bladder adenocarcinoma (PBAC). Loss of MMR proteins (MLH1, MSH2, MSH6, and PMS2) additionally favors
colorectal over urachal adenocarcinomas. For more details on reactivity rates, number of cases, and references, please refer to
Supplementary Table 2. Please note that data density is low for most antibodies limiting significance. “Highest” data quality is available for
CK7, β-Catenin, and CEA.−: negative (0% positive); (−): mostly negative (1–25% positive); +/−: some positive (26–50% positive); (+):
mostly positive (51–75% positive); +: positive (76–100% positive).
Reactivity Differential diagnosis
Biomarker (IHC) UrC CRC PBAC UrC versus CRC and PBAC UrC and PBAC versus CRC UrC and CRC versus PBAC
AMACR (p504s) (−) + (+) + − −
CK34βE12 (HMWCK) (+) (−) +/− + − −
CK7 (+) +/− (+) − + −
β-Catenin (nuclear) (−) + (−) − + −
CD15 (Leu-M1) + +/− (+) − + −
CEA + + (+) − − +
GATA3 − − (+) − − +
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and lower rates in colorectal and primary bladder adenocar-
cinomas, however, with significant overlap [86, 95, 100, 125,
128, 251, 335, 346, 347].
In contrast, CD15 was detected in high rates of both ura-
chal and primary bladder adenocarcinomas (86% and 73%,
resp.) compared to colorectal adenocarcinomas with a lower
reactivity rate (<50%) [21, 27, 124, 125, 348]. CEA was
opposingly found to be positive in all analyzed cases of ura-
chal adenocarcinomas and in a similarly high rate of colorec-
tal adenocarcinomas but lower rates in primary bladder
adenocarcinomas (29–67%) [21, 27, 48, 60, 67, 77, 86, 100,
106, 124, 163, 165, 245, 255, 348–353].
Finally, GATA3 was not found to be expressed in urachal
adenocarcinomas and colorectal adenocarcinomas but in
approximately half of cases of primary bladder adenocarci-
nomas [335, 354, 355]. In addition, nuclear GATA3 reactivity
might be useful in the differential diagnosis of bladder adeno-
carcinomas with signet ring morphology [355].
The example of GATA3 in particular illustrates the
need of rigorous case selection of primary bladder and/or
urachal adenocarcinomas in the studies. Inclusion of UC
with glandular differentiation or plasmacytoid UC could
significantly weaken the validity of such a study and there-
fore its conclusions.
The distribution of the DNA mismatch repair (MMR)
proteins, that is, MutL homolog 1 (MLH1), MutS homolog
2 (MSH2), MutS homolog 6 (MSH6), and PMS1 homolog 2
(PMS2), in the different entities might in addition also be of
differential diagnostic and pathogenetic interest. While no
data is available for primary bladder adenocarcinomas, spo-
radic colorectal adenocarcinomas exhibit a loss of MMR pro-
teins in 10–15% in total with emphasis on MLH1 [356]. In
urachal adenocarcinomas, some tumors with microsatellite
instability characterized by immunohistochemistry were
described [25]. We, however, detected no loss of MMR pro-
teins by immunohistochemistry in our own institutional
cases (n = 12). In additional preliminary molecular analyses,
we also did not detect evidence of microsatellite instability
(unpublished data). This seems to point to molecular differ-
ences in adenocarcinomas of urachal and colorectal origin.
Further important biomarkers in differential diagnostic
considerations of adenocarcinomas in general are hormone
receptors. In our review data, urachal adenocarcinomas did
not express estrogen and progesterone receptors by immu-
nohistochemistry, which might be of particular interest in
the discrimination of a metastasis of urachal adenocarci-
nomas to the ovary and vice versa [17, 56, 67]. In this set-
ting, the immunonegativity of urachal adenocarcinomas
for cancer antigen 125 (CA125) might also be of value, how-
ever, with the limitation of only 8 cases reported in the liter-
ature [27, 60, 86].
Low numbers of cases and no differential diagnostic value
regarding the discrimination of urachal adenocarcinomas
from primary bladder and colorectal adenocarcinomas were
detected for α-fetoprotein (AFP), carbohydrate antigen 19-9
(CA19-9), cluster of differentiation 10 (CD10), CK19,
Das-1, E48, E-Cadherin, gross cystic disease fluid protein
15 (GCDFP15), mucin 1 (epithelial membrane antigen)
(MUC1 (EMA)), mucin 6 (MUC6), Thrombmodulin,
thyroid transcription factor 1 (TTF1), Uroplakin III, Villin,
and Vimentin [27, 48, 60, 86, 100, 106, 125, 126, 172, 198,
215, 217, 245, 292, 330].
However, this might not be the case for some rare and
special differential diagnostic considerations as for example
in the discrimination of ductal prostate cancer and the
enteric type of urachal adenocarcinomas, in which immuno-
histochemistry for prostate specific acid phosphatase (PAP)
and prostate-specific antigen (PSA) (both negative in urachal
adenocarcinomas and positive in ductal prostate cancer)
might be useful [21, 27, 74, 77, 100, 245, 255, 357].
In addition to the differential diagnostic context, immu-
nohistochemical markers might be of further clinical value.
We recently assessed the expression and prognostic rele-
vance of six immunohistochemical markers (Ki67, p53,
biglycan (BGN), receptor for hyaluronan-mediated motility
(RHAMM), and insulin-like growth factor II mRNA binding
protein 3 (IMP3)) in urachal adenocarcinomas. RHAMM,
IMP3, Ki67, and p53 were found to be increased in urachal
adenocarcinomas. However, none of the analyzed markers
exhibited any prognostic information [15].
Although immunohistochemical biomarkers are widely
used in differential diagnostic considerations, their interpre-
tation is per se subjective. This applies in every situation in
which these markers are used and therefore also in the
immunohistochemical differential diagnosis of UrC. A fur-
ther limitation of the collected data might also be the thresh-
old at which the authors of the different source studies called
an immunohistochemical marker positive or negative. Often-
times, this information is missing while it can be very impor-
tant. For example, the decision to call a case positive for
nuclear β-Catenin might depend only on a few stained tumor
nuclei but with important differential diagnostic implications
[23, 329].
These considerations and also the partly overlapping
positivity rates of the different immunohistochemical
biomarkers make it difficult to recommend a step wise
biomarker-guided approach. This could create a false sense
of sensitivity and specificity of the biomarkers in the different
situations. From our experience, immunohistochemical
staining of a panel of antibodies, which depends on the differ-
ential diagnostic setting (Table 2), is the best way to come to a
conclusion in this setting. This process might of course also
include the use of further antibodies in addition to the core
panel and always lies in the expertise of the diagnostic
histopathologist.
8. Biomarkers in Urachal Cancer:
Serum Markers
The (histomorphological) parallels between urachal and
colorectal adenocarcinomas furthermore gave the rationale
to test colorectal tumor markers in serum samples of
patients with urachal adenocarcinomas, especially CEA,
CA19-9, and CA125. In CRC, these markers are elevated
in approximately one third (CA125), half (CA19-9), and
two-thirds (CEA) of patients with a considerable variance
depending on tumor size and other variables [358]. In pri-
mary bladder adenocarcinomas, however, only sporadic
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data is available with reports of elevated serum levels of
these markers [359, 360].
In urachal adenocarcinomas, 44 studies including data on
serum parameters were available, including 7 original studies
and 37 case reports with a total of 140 patients.
Siefker-Radtke and colleagues reported on the largest
cohort and found elevated (>3 ng/ml) CEA serum levels in
59% of patients with urachal adenocarcinomas (median:
36 ng/ml) [24]. In 5 cases, CEA also decreased in response
to chemotherapy, suggesting the potential utility of CEA test-
ing in monitoring (or follow-up) of UrC. When analyzing the
literature, elevated CEA serum levels were reported in 55.7%
(59/106) of patients at the time of diagnosis [24, 26, 33, 42,
60, 67, 79, 80, 86, 88, 89, 95, 99, 106, 118, 128, 131, 149,
156, 163–165, 167, 179, 196, 200, 207, 208, 212, 214, 240,
241, 244, 246, 251]. In our analyses, elevated CEA levels at
diagnosis were associated with worse OS (p = 0 008) and
PFS (p = 0 009) in dichotomized analyses (elevated versus
normal), however, with only sparse survival data.
Additionally, elevated serum levels of CA19-9 and
CA125 were reported in 50.8% (31/61) and 51.4% (19/37),
respectively [24, 26, 33, 42, 76, 79–81, 86, 88, 89, 95, 99,
104, 114, 128, 149, 168, 200, 207, 213, 240, 244, 246, 251].
As with CEA, elevated levels of CA19-9 exhibited a trend
towards worse OS and PFS (both p = 0 09). No prognostic
association was noted for CA125. In addition, elevated serum
levels of CA125 did not correlate with negative immunohis-
tochemical tissue expression, however, with a low case num-
ber (n = 8).
Other serum biomarkers reported in low case numbers of
urachal adenocarcinomas include lactate dehydrogenase
(LDH) [80, 199], cancer antigen 15-3 (CA15-3) [26, 114,
156], AFP [16, 42, 95, 106, 156] with one case in a seven-
month-old infant with a yolk sac tumor of the urachus
[295], and neuron-specific enolase (NSE) [156] including
one case of a neuroblastoma in a six-month-old child [296].
In summary, measurement of serum biomarkers might
be useful in the follow-up and disease monitoring of UrC.
9. Conclusions
We identified a total of 1984 cases of UrC from 319 suitable
studies with sufficient data from the English literature with
overall 1834 adenocarcinomas (92%). While only minor var-
iations in clinicopathological factors such as gender distribu-
tion (male preponderance), age at diagnosis, tumor size, and
adenocarcinoma subtypes were noted, none of these factors
were associated with overall survival. However, regarding
progression-free survival, an advantage for male patients
especially in the adenocarcinoma cohort was noted, while
no such association was observed for nonglandular neo-
plasms of urachal origin.
The summary of existing evidence on immunohisto-
chemical markers supplemented with our own data
highlighted a differential diagnostic role for AMACR,
CK34βE12, CK7, β-Catenin, CD15, and CEA (Table 2)
which can be helpful in the routine differential diagnostic
workup of adenocarcinomas in the bladder. Also, GATA3
might be helpful in the differentiation of urachal from
primary bladder adenocarcinomas, with data presented
almost exclusively derived from our institutional cohort. In
addition, serum markers such as CEA, CA19-9, and CA125
might be useful in the follow-up and monitoring of UrC
while CEA and CA19-9 may also be of prognostic value.
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Supplementary Materials
Supplementary Table 1(a): Detailed information on used
antibodies and protocol in the cohort of the UrC register of
the University Hospital of Essen. Supplementary Table
1(b): IHC results in the analyzed cohort of the UrC register
of the University Hospital of Essen Detection of any immu-
noreactivity in the tumor cells was assessed as positive and
complete lack of immunoreactivity as negative. For β-
Catenin, the nuclear (nuc.) and membranous/cytoplasmic
(m/c) reactivities were analyzed separately. The DNA mis-
match repair proteins MLH1, MSH2, MSH6, and PMS2 were
evaluated as positive if more than 10% of tumor cells exhib-
ited a nuclear immunoreactivity. Specific immunostaining
was cytoplasmic in case of CD15, CEA, CK7, and CK20
and nuclear in case of CDX2 and GATA3. Supplementary
Table 2: detailed information on immunohistochemical bio-
marker expression in urachal adenocarcinomas (UrC ADC)
including own data (∗ ) in comparison to figures from the lit-
erature for colorectal (CRC) and primary bladder adenocar-
cinomas (PBAC). This table includes information about
markers of potential differential diagnostic usefulness in
UrC versus CRC and PBAC, UrC and PBAC versus CRC,
and UrC and CRC versus PBAC. ^ is positive in hepatoid
carcinomas of the urinary bladder [329]; ^^ is usually pos-
itive in clear cell PBAC [329]; ^^^Figures for sporadic
colorectal cancer (nonhereditary), total loss of MMR pro-
teins is evident in 10–15% of sporadic colorectal cancers
[356] ∗Own data from the UrC register of the University
Hospital of Essen is included to increase data quality (all:
n = 12, but CK7: n = 11). [15] UrC: urachal cancer; ADC:
adenocarcinoma; AFP: α-fetoprotein; AMACR: alpha-
methylacyl-CoA racemase; mem/cyt: membranous/cyto-
plasmic immunoreactivity; β-Catenin: β-Catenin; CA19-9:
carbohydrate antigen 19-9; CA125: cancer antigen 125;
CD10: cluster of differentiation 10; CD15: cluster of differ-
entiation 15; CDX2: caudal-type homeobox protein 2; CEA:
carcinoembryonic antigen; CK7: cytokeratin 7; CK19: cyto-
keratin 19; CK20: cytokeratin 20; CK34βE12 (HMWCK):
cytokeratin 34 (1,5,10,14) (high-molecular weight cytokera-
tin); ER: estrogen receptor; GATA3: GATA binding protein
3; GCDFP15: Gross cystic disease fluid protein 15; HER2:
human epidermal growth factor receptor 2; MMR: DNA
mismatch repair proteins; MLH1: mutL homolog 1;
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MSH2: mutS homolog 2; MSH6: mutS homolog 6; MUC1
(EMA): mucin 1, cell surface associated (epithelial membrane
antigen); MUC2: mucin 2, oligomeric mucus/gel-forming;
MUC5AC: mucin 5AC oligomeric mucus/gel-forming;
MUC6: mucin 6, oligomeric mucus/gel-forming; PR: proges-
terone receptor; PSAP: prostatic specific acid phosphatase;
PSA: prostate-specific antigen; PMS2: PMS1 homolog 2;
RegIV: Regenerating gene IV; TTF1: thyroid transcription
factor 1 (NK2 homeobox 1). Supplementary Figure 1:
progression-free survival in urachal adenocarcinomas regard-
ing gender [1, 15, 17, 21, 23, 25–27, 31, 36, 48, 56, 60, 62, 67, 74,
77, 86, 95, 99, 100, 106, 124–126, 128, 148, 156, 163–165, 172,
198, 215–217, 220, 221, 240, 245, 251, 255, 292, 327–335, 338–
355, 361–388]. (Supplementary Materials)
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